244 related articles for article (PubMed ID: 12870129)
1. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis.
Murray HW; Moreira AL; Lu CM; DeVecchio JL; Matsuhashi M; Ma X; Heinzel FP
J Infect Dis; 2003 Aug; 188(3):458-64. PubMed ID: 12870129
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 10 receptor blockade--pentavalent antimony treatment in experimental visceral leishmaniasis.
Murray HW
Acta Trop; 2005 Mar; 93(3):295-301. PubMed ID: 15716043
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.
Murray HW; Lu CM; Mauze S; Freeman S; Moreira AL; Kaplan G; Coffman RL
Infect Immun; 2002 Nov; 70(11):6284-93. PubMed ID: 12379707
[TBL] [Abstract][Full Text] [Related]
4. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma.
Murray HW; Stern JJ; Welte K; Rubin BY; Carriero SM; Nathan CF
J Immunol; 1987 Apr; 138(7):2290-7. PubMed ID: 3104456
[TBL] [Abstract][Full Text] [Related]
5. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis.
Murray HW; Montelibano C; Peterson R; Sypek JP
J Infect Dis; 2000 Nov; 182(5):1497-502. PubMed ID: 11023473
[TBL] [Abstract][Full Text] [Related]
7. Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response.
Squires KE; Schreiber RD; McElrath MJ; Rubin BY; Anderson SL; Murray HW
J Immunol; 1989 Dec; 143(12):4244-9. PubMed ID: 2512353
[TBL] [Abstract][Full Text] [Related]
8. Role and effect of IL-2 in experimental visceral leishmaniasis.
Murray HW; Miralles GD; Stoeckle MY; McDermott DF
J Immunol; 1993 Jul; 151(2):929-38. PubMed ID: 8335921
[TBL] [Abstract][Full Text] [Related]
9. Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase.
Murray HW; Xiang Z; Ma X
Am J Trop Med Hyg; 2006 Jun; 74(6):1013-5. PubMed ID: 16760512
[TBL] [Abstract][Full Text] [Related]
10. Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity.
Murray HW; Squires KE; Miralles CD; Stoeckle MY; Granger AM; Granelli-Piperno A; Bogdan C
J Immunol; 1992 Mar; 148(6):1858-63. PubMed ID: 1541824
[TBL] [Abstract][Full Text] [Related]
11. Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice.
Sato N; Kuziel WA; Melby PC; Reddick RL; Kostecki V; Zhao W; Maeda N; Ahuja SK; Ahuja SS
J Immunol; 1999 Nov; 163(10):5519-25. PubMed ID: 10553079
[TBL] [Abstract][Full Text] [Related]
12. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology.
Satoskar AR; Rodig S; Telford SR; Satoskar AA; Ghosh SK; von Lichtenberg F; David JR
Eur J Immunol; 2000 Mar; 30(3):834-9. PubMed ID: 10741399
[TBL] [Abstract][Full Text] [Related]
13. The TGF-beta response to Leishmania chagasi in the absence of IL-12.
Wilson ME; Recker TJ; Rodriguez NE; Young BM; Burnell KK; Streit JA; Kline JN
Eur J Immunol; 2002 Dec; 32(12):3556-65. PubMed ID: 12516540
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of interferon-gamma and mannosylated liposome-incorporated doxorubicin in the therapy of experimental visceral leishmaniasis.
Kole L; Das L; Das PK
J Infect Dis; 1999 Sep; 180(3):811-20. PubMed ID: 10438370
[TBL] [Abstract][Full Text] [Related]
15. TLR-mediated distinct IFN-γ/IL-10 pattern induces protective immunity against murine visceral leishmaniasis.
Paul J; Karmakar S; De T
Eur J Immunol; 2012 Aug; 42(8):2087-99. PubMed ID: 22622993
[TBL] [Abstract][Full Text] [Related]
16. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.
Kushawaha PK; Gupta R; Sundar S; Sahasrabuddhe AA; Dube A
J Immunol; 2011 Dec; 187(12):6417-27. PubMed ID: 22079980
[TBL] [Abstract][Full Text] [Related]
17. NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs.
Schleicher U; Liese J; Knippertz I; Kurzmann C; Hesse A; Heit A; Fischer JA; Weiss S; Kalinke U; Kunz S; Bogdan C
J Exp Med; 2007 Apr; 204(4):893-906. PubMed ID: 17389237
[TBL] [Abstract][Full Text] [Related]
18. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis.
Murray HW; Delph-Etienne S
Infect Immun; 2000 Jan; 68(1):288-93. PubMed ID: 10603400
[TBL] [Abstract][Full Text] [Related]
19. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
Bhowmick S; Ravindran R; Ali N
Vaccine; 2007 Aug; 25(35):6544-56. PubMed ID: 17655984
[TBL] [Abstract][Full Text] [Related]
20. Role of IL-12 in macrophage activation during intracellular infection: IL-12 and mycobacteria synergistically release TNF-alpha and nitric oxide from macrophages via IFN-gamma induction.
Xing Z; Zganiacz A; Santosuosso M
J Leukoc Biol; 2000 Dec; 68(6):897-902. PubMed ID: 11129658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
